Titre : Protein-tyrosine kinases

Protein-tyrosine kinases : Questions médicales fréquentes

Nom anglais: Protein-Tyrosine Kinases

Descriptor UI: D011505

Tree Number: D12.776.476.568

Termes MeSH sélectionnés :

Network Meta-Analysis

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dysrégulation des kinases à tyrosine ?

Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases.
Kinases Biopsie Tests sanguins
#2

Quels marqueurs sont utilisés pour le diagnostic ?

Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale.
Marqueurs tumoraux Kinases CA 19-9
#3

Les tests génétiques sont-ils utiles ?

Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine.
Tests génétiques Mutations Kinases
#4

Quels examens d'imagerie sont recommandés ?

L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases.
IRM Scanner Tumeurs
#5

Les antécédents familiaux influencent-ils le diagnostic ?

Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases.
Antécédents familiaux Cancer Kinases

Symptômes 5

#1

Quels symptômes sont liés à une suractivité des kinases ?

Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases.
Fatigue Perte de poids Kinases
#2

Les symptômes varient-ils selon le type de kinase ?

Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée.
Kinases Voies de signalisation Symptômes
#3

Y a-t-il des symptômes spécifiques aux cancers ?

Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir.
Cancers Masse palpable Saignements
#4

Les symptômes peuvent-ils être confondus avec d'autres maladies ?

Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies.
Fatigue Maladies Symptômes
#5

Comment les symptômes évoluent-ils dans le temps ?

Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière.
Évolution des symptômes Surveillance Kinases

Prévention 5

#1

Peut-on prévenir les dysfonctionnements des kinases ?

Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers.
Prévention Alimentation saine Exercice
#2

Les dépistages réguliers sont-ils recommandés ?

Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases.
Dépistage Anomalies Kinases
#3

Y a-t-il des vaccins préventifs ?

Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases.
Vaccins Prévention Kinases
#4

Le tabagisme influence-t-il le risque ?

Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases.
Tabagisme Facteurs de risque Kinases
#5

Les facteurs environnementaux jouent-ils un rôle ?

Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases.
Facteurs environnementaux Substances chimiques Kinases

Traitements 5

#1

Quels traitements ciblent les kinases à tyrosine ?

Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers.
Inhibiteurs de kinases Imatinib Traitements
#2

Les traitements sont-ils personnalisés ?

Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases.
Traitements personnalisés Mutations Kinases
#3

Quels effets secondaires des traitements sont courants ?

Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents.
Effets secondaires Fatigue Nausées
#4

La radiothérapie est-elle utilisée ?

Oui, la radiothérapie peut être utilisée en complément des traitements ciblés.
Radiothérapie Traitements ciblés Kinases
#5

Les traitements sont-ils efficaces à long terme ?

L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée.
Efficacité des traitements Rémission Kinases

Complications 5

#1

Quelles complications peuvent survenir avec les kinases ?

Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir.
Complications Résistance aux traitements Progression de la maladie
#2

Les complications sont-elles réversibles ?

Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes.
Complications Gestion Kinases
#3

Comment les complications affectent-elles le pronostic ?

Les complications peuvent aggraver le pronostic et réduire les chances de rémission.
Pronostic Complications Rémission
#4

Les complications varient-elles selon le type de cancer ?

Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée.
Type de cancer Complications Kinases
#5

Les complications nécessitent-elles des traitements supplémentaires ?

Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications.
Traitements supplémentaires Complications Kinases

Facteurs de risque 5

#1

Quels sont les principaux facteurs de risque ?

Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque.
Facteurs de risque Antécédents familiaux Tabagisme
#2

L'âge influence-t-il le risque de dysfonctionnement des kinases ?

Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers.
Âge Risque Kinases
#3

Le mode de vie joue-t-il un rôle ?

Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque.
Mode de vie Risque Kinases
#4

Les infections peuvent-elles être un facteur de risque ?

Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque.
Infections Virus d'Epstein-Barr Risque
#5

Y a-t-il des facteurs génétiques impliqués ?

Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases.
Facteurs génétiques Mutations Kinases
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protein-tyrosine kinases : Questions médicales les plus fréquentes", "headline": "Protein-tyrosine kinases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protein-tyrosine kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-05", "dateModified": "2025-04-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protein-tyrosine kinases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines et peptides de signalisation intracellulaire", "url": "https://questionsmedicales.fr/mesh/D047908", "about": { "@type": "MedicalCondition", "name": "Protéines et peptides de signalisation intracellulaire", "code": { "@type": "MedicalCode", "code": "D047908", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Agammaglobulinaemia tyrosine kinase", "alternateName": "Agammaglobulinaemia Tyrosine Kinase", "url": "https://questionsmedicales.fr/mesh/D000077329", "about": { "@type": "MedicalCondition", "name": "Agammaglobulinaemia tyrosine kinase", "code": { "@type": "MedicalCode", "code": "D000077329", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.025" } } }, { "@type": "MedicalWebPage", "name": "Focal adhesion protein-tyrosine kinases", "alternateName": "Focal Adhesion Protein-Tyrosine Kinases", "url": "https://questionsmedicales.fr/mesh/D051416", "about": { "@type": "MedicalCondition", "name": "Focal adhesion protein-tyrosine kinases", "code": { "@type": "MedicalCode", "code": "D051416", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.049" } } }, { "@type": "MedicalWebPage", "name": "Janus kinases", "alternateName": "Janus Kinases", "url": "https://questionsmedicales.fr/mesh/D053612", "about": { "@type": "MedicalCondition", "name": "Janus kinases", "code": { "@type": "MedicalCode", "code": "D053612", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.124" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Janus kinase 1", "alternateName": "Janus Kinase 1", "url": "https://questionsmedicales.fr/mesh/D053613", "about": { "@type": "MedicalCondition", "name": "Janus kinase 1", "code": { "@type": "MedicalCode", "code": "D053613", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.124.100" } } }, { "@type": "MedicalWebPage", "name": "Janus kinase 3", "alternateName": "Janus Kinase 3", "url": "https://questionsmedicales.fr/mesh/D053616", "about": { "@type": "MedicalCondition", "name": "Janus kinase 3", "code": { "@type": "MedicalCode", "code": "D053616", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.124.300" } } }, { "@type": "MedicalWebPage", "name": "TYK2 Kinase", "alternateName": "TYK2 Kinase", "url": "https://questionsmedicales.fr/mesh/D053634", "about": { "@type": "MedicalCondition", "name": "TYK2 Kinase", "code": { "@type": "MedicalCode", "code": "D053634", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.124.650" } } } ] }, { "@type": "MedicalWebPage", "name": "Mitogen-Activated Protein Kinase Kinases", "alternateName": "Mitogen-Activated Protein Kinase Kinases", "url": "https://questionsmedicales.fr/mesh/D020929", "about": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase Kinases", "code": { "@type": "MedicalCode", "code": "D020929", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 1", "alternateName": "MAP Kinase Kinase 1", "url": "https://questionsmedicales.fr/mesh/D048369", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 1", "code": { "@type": "MedicalCode", "code": "D048369", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.100" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 2", "alternateName": "MAP Kinase Kinase 2", "url": "https://questionsmedicales.fr/mesh/D048370", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 2", "code": { "@type": "MedicalCode", "code": "D048370", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.200" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 3", "alternateName": "MAP Kinase Kinase 3", "url": "https://questionsmedicales.fr/mesh/D048371", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 3", "code": { "@type": "MedicalCode", "code": "D048371", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.300" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 4", "alternateName": "MAP Kinase Kinase 4", "url": "https://questionsmedicales.fr/mesh/D048670", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 4", "code": { "@type": "MedicalCode", "code": "D048670", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.400" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 5", "alternateName": "MAP Kinase Kinase 5", "url": "https://questionsmedicales.fr/mesh/D048671", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 5", "code": { "@type": "MedicalCode", "code": "D048671", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.500" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 6", "alternateName": "MAP Kinase Kinase 6", "url": "https://questionsmedicales.fr/mesh/D048669", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 6", "code": { "@type": "MedicalCode", "code": "D048669", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.600" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 7", "alternateName": "MAP Kinase Kinase 7", "url": "https://questionsmedicales.fr/mesh/D048688", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 7", "code": { "@type": "MedicalCode", "code": "D048688", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.700" } } } ] }, { "@type": "MedicalWebPage", "name": "Syk kinase", "alternateName": "Syk Kinase", "url": "https://questionsmedicales.fr/mesh/D000072377", "about": { "@type": "MedicalCondition", "name": "Syk kinase", "code": { "@type": "MedicalCode", "code": "D000072377", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.650" } } }, { "@type": "MedicalWebPage", "name": "src-Family kinases", "alternateName": "src-Family Kinases", "url": "https://questionsmedicales.fr/mesh/D019061", "about": { "@type": "MedicalCondition", "name": "src-Family kinases", "code": { "@type": "MedicalCode", "code": "D019061", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.800" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "CSK tyrosine-protein kinase", "alternateName": "CSK Tyrosine-Protein Kinase", "url": "https://questionsmedicales.fr/mesh/D000081247", "about": { "@type": "MedicalCondition", "name": "CSK tyrosine-protein kinase", "code": { "@type": "MedicalCode", "code": "D000081247", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.800.158" } } } ] }, { "@type": "MedicalWebPage", "name": "ZAP-70 Protein-tyrosine kinase", "alternateName": "ZAP-70 Protein-Tyrosine Kinase", "url": "https://questionsmedicales.fr/mesh/D051746", "about": { "@type": "MedicalCondition", "name": "ZAP-70 Protein-tyrosine kinase", "code": { "@type": "MedicalCode", "code": "D051746", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Protein-tyrosine kinases", "alternateName": "Protein-Tyrosine Kinases", "code": { "@type": "MedicalCode", "code": "D011505", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Angela L Tyner", "url": "https://questionsmedicales.fr/author/Angela%20L%20Tyner", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu." } }, { "@type": "Person", "name": "Eiji Kinoshita", "url": "https://questionsmedicales.fr/author/Eiji%20Kinoshita", "affiliation": { "@type": "Organization", "name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan." } }, { "@type": "Person", "name": "Emiko Kinoshita-Kikuta", "url": "https://questionsmedicales.fr/author/Emiko%20Kinoshita-Kikuta", "affiliation": { "@type": "Organization", "name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan." } }, { "@type": "Person", "name": "Tohru Koike", "url": "https://questionsmedicales.fr/author/Tohru%20Koike", "affiliation": { "@type": "Organization", "name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan." } }, { "@type": "Person", "name": "Gongqin Sun", "url": "https://questionsmedicales.fr/author/Gongqin%20Sun", "affiliation": { "@type": "Organization", "name": "Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "How To Read a Network Meta-analysis.", "datePublished": "2023-11-03", "url": "https://questionsmedicales.fr/article/37925328", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.euf.2023.10.018" } }, { "@type": "ScholarlyArticle", "name": "Methodological quality of network meta-analysis in dentistry: a meta-research.", "datePublished": "2023-07-10", "url": "https://questionsmedicales.fr/article/37436290", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/1807-3107bor-2023.vol37.0062" } }, { "@type": "ScholarlyArticle", "name": "Effects of non-pharmacological interventions for adults with subjective cognitive decline: a network meta-analysis and component network meta-analysis.", "datePublished": "2024-06-27", "url": "https://questionsmedicales.fr/article/38937777", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12916-024-03491-z" } }, { "@type": "ScholarlyArticle", "name": "Network meta-interpolation: Effect modification adjustment in network meta-analysis using subgroup analyses.", "datePublished": "2022-11-04", "url": "https://questionsmedicales.fr/article/36283960", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jrsm.1608" } }, { "@type": "ScholarlyArticle", "name": "Treatments for alopecia areata: a network meta-analysis.", "datePublished": "2023-10-23", "url": "https://questionsmedicales.fr/article/37870096", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD013719.pub2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-tyrosine kinases", "item": "https://questionsmedicales.fr/mesh/D011505" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protein-tyrosine kinases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protein-tyrosine kinases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protein-tyrosine kinases", "description": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?\nQuels marqueurs sont utilisés pour le diagnostic ?\nLes tests génétiques sont-ils utiles ?\nQuels examens d'imagerie sont recommandés ?\nLes antécédents familiaux influencent-ils le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Network+Meta-Analysis&page=1#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protein-tyrosine kinases", "description": "Quels symptômes sont liés à une suractivité des kinases ?\nLes symptômes varient-ils selon le type de kinase ?\nY a-t-il des symptômes spécifiques aux cancers ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils dans le temps ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Network+Meta-Analysis&page=1#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protein-tyrosine kinases", "description": "Peut-on prévenir les dysfonctionnements des kinases ?\nLes dépistages réguliers sont-ils recommandés ?\nY a-t-il des vaccins préventifs ?\nLe tabagisme influence-t-il le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Network+Meta-Analysis&page=1#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protein-tyrosine kinases", "description": "Quels traitements ciblent les kinases à tyrosine ?\nLes traitements sont-ils personnalisés ?\nQuels effets secondaires des traitements sont courants ?\nLa radiothérapie est-elle utilisée ?\nLes traitements sont-ils efficaces à long terme ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Network+Meta-Analysis&page=1#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protein-tyrosine kinases", "description": "Quelles complications peuvent survenir avec les kinases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le pronostic ?\nLes complications varient-elles selon le type de cancer ?\nLes complications nécessitent-elles des traitements supplémentaires ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Network+Meta-Analysis&page=1#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protein-tyrosine kinases", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de dysfonctionnement des kinases ?\nLe mode de vie joue-t-il un rôle ?\nLes infections peuvent-elles être un facteur de risque ?\nY a-t-il des facteurs génétiques impliqués ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Network+Meta-Analysis&page=1#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases." } }, { "@type": "Question", "name": "Quels marqueurs sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine." } }, { "@type": "Question", "name": "Quels examens d'imagerie sont recommandés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une suractivité des kinases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de kinase ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques aux cancers ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils dans le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements des kinases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases." } }, { "@type": "Question", "name": "Y a-t-il des vaccins préventifs ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il le risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases." } }, { "@type": "Question", "name": "Quels traitements ciblent les kinases à tyrosine ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases." } }, { "@type": "Question", "name": "Quels effets secondaires des traitements sont courants ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la radiothérapie peut être utilisée en complément des traitements ciblés." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces à long terme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les kinases ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment les complications affectent-elles le pronostic ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent aggraver le pronostic et réduire les chances de rémission." } }, { "@type": "Question", "name": "Les complications varient-elles selon le type de cancer ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée." } }, { "@type": "Question", "name": "Les complications nécessitent-elles des traitements supplémentaires ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de dysfonctionnement des kinases ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers." } }, { "@type": "Question", "name": "Le mode de vie joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } }, { "@type": "Question", "name": "Les infections peuvent-elles être un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques impliqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale

Validation scientifique effectuée le 30/04/2025

Contenu vérifié selon les dernières recommandations médicales

En savoir plus sur Dr Menir

Sous-catégories

18 au total
└─

Agammaglobulinaemia tyrosine kinase

Agammaglobulinaemia Tyrosine Kinase D000077329 - D12.776.476.568.025
└─

Focal adhesion protein-tyrosine kinases

Focal Adhesion Protein-Tyrosine Kinases D051416 - D12.776.476.568.049
└─

Janus kinases

Janus Kinases D053612 - D12.776.476.568.124
└─

Mitogen-Activated Protein Kinase Kinases

Mitogen-Activated Protein Kinase Kinases D020929 - D12.776.476.568.200
└─

Syk kinase

Syk Kinase D000072377 - D12.776.476.568.650
└─

src-Family kinases

src-Family Kinases D019061 - D12.776.476.568.800
└─

ZAP-70 Protein-tyrosine kinase

ZAP-70 Protein-Tyrosine Kinase D051746 - D12.776.476.568.900
└─└─

Janus kinase 1

Janus Kinase 1 D053613 - D12.776.476.568.124.100
└─└─

Janus kinase 3

Janus Kinase 3 D053616 - D12.776.476.568.124.300
└─└─

TYK2 Kinase

TYK2 Kinase D053634 - D12.776.476.568.124.650
└─└─

MAP Kinase Kinase 1

MAP Kinase Kinase 1 D048369 - D12.776.476.568.200.100
└─└─

MAP Kinase Kinase 2

MAP Kinase Kinase 2 D048370 - D12.776.476.568.200.200
└─└─

MAP Kinase Kinase 3

MAP Kinase Kinase 3 D048371 - D12.776.476.568.200.300
└─└─

MAP Kinase Kinase 4

MAP Kinase Kinase 4 D048670 - D12.776.476.568.200.400
└─└─

MAP Kinase Kinase 5

MAP Kinase Kinase 5 D048671 - D12.776.476.568.200.500
└─└─

MAP Kinase Kinase 6

MAP Kinase Kinase 6 D048669 - D12.776.476.568.200.600
└─└─

MAP Kinase Kinase 7

MAP Kinase Kinase 7 D048688 - D12.776.476.568.200.700
└─└─

CSK tyrosine-protein kinase

CSK Tyrosine-Protein Kinase D000081247 - D12.776.476.568.800.158

Auteurs principaux

Angela L Tyner

3 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu.
Publications dans "Protein-tyrosine kinases" :

Eiji Kinoshita

3 publications dans cette catégorie

Affiliations :
  • Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :

Emiko Kinoshita-Kikuta

3 publications dans cette catégorie

Affiliations :
  • Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :

Tohru Koike

3 publications dans cette catégorie

Affiliations :
  • Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :

Gongqin Sun

3 publications dans cette catégorie

Affiliations :
  • Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States.
Publications dans "Protein-tyrosine kinases" :

Wanian M Alwanian

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA.
Publications dans "Protein-tyrosine kinases" :

Swati Jaiswal

2 publications dans cette catégorie

Affiliations :
  • University of Massachusetts Chan Medical School, Worcester, United States. Electronic address: swati.jaiswal@umassmed.edu.
Publications dans "Protein-tyrosine kinases" :

Terry W Moody

2 publications dans cette catégorie

Affiliations :
  • Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.
Publications dans "Protein-tyrosine kinases" :

Robert T Jensen

2 publications dans cette catégorie

Affiliations :
  • Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.
Publications dans "Protein-tyrosine kinases" :

Cristina Lao-Peregrin

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Guoqing Xiang

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Jihye Kim

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Ipsit Srivastava

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Alexandra B Fall

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Danielle M Gerhard

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Piia Kohtala

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Daegeon Kim

2 publications dans cette catégorie

Affiliations :
  • Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :

Minseok Song

2 publications dans cette catégorie

Affiliations :
  • Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :

Mikel Garcia-Marcos

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
Publications dans "Protein-tyrosine kinases" :

Joshua Levitz

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: jtl2003@med.cornell.edu.
Publications dans "Protein-tyrosine kinases" :

Sources (10000 au total)

Effects of non-pharmacological interventions for adults with subjective cognitive decline: a network meta-analysis and component network meta-analysis.

27 Jun 2024
DOI: 10.1186/s12916-024-03491-z PMID: 38937777

Non-pharmacological interventions have a myriad of available intervention options and contain multiple components. Whether specific components of non-pharmacological interventions or combinations are ... PubMed, Embase, Cochrane, CINAHL, PsycINFO, CENTRAL, Web of Science, and China's two largest databases, CNKI and Wanfang, were searched from inception to 22nd, January 2023. Randomized controlled tria... A total of 39 trials with 2959 patients were included (range of mean ages, 58.79-77.41 years). Resistance exercise might be the optimal intervention for reducing memory complaints in adults with subje... The form of physical activity performed appears to be more beneficial than cognitive interventions in reducing subjective memory complaints for adults with subjective cognitive decline, and this diffe... PROSPERO registry number. CRD42022355363....

Humans Cognitive Dysfunction Network Meta-Analysis Middle Aged Aged +2 autres

Treatments for alopecia areata: a network meta-analysis.

23 10 2023
DOI: 10.1002/14651858.CD013719.pub2 PMID: 37870096

Alopecia areata is an autoimmune disease leading to nonscarring hair loss on the scalp or body. There are different treatments including immunosuppressants, hair growth stimulants, and contact immunot... To assess the benefits and harms of the treatments for alopecia areata (AA), alopecia totalis (AT), and alopecia universalis (AU) in children and adults.... The Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, ClinicalTrials.gov and WHO ICTRP were searched up to July 2022.... We included randomised controlled trials (RCTs) that evaluated classical immunosuppressants, biologics, small molecule inhibitors, contact immunotherapy, hair growth stimulants, and other therapies in... We used the standard procedures expected by Cochrane including assessment of risks of bias using RoB2 and the certainty of the evidence using GRADE. The primary outcomes were short-term hair regrowth ... We included 63 studies that tested 47 different treatments in 4817 randomised participants. All trials used a parallel-group design except one that used a cross-over design. The mean sample size was 7... We found that treatment with baricitinib results in an increase in short- and long-term hair regrowth compared to placebo. Although we found inconclusive results for the risk of serious adverse effect...

Adult Humans Child Child, Preschool Adolescent +11 autres

Does type of funding affect reporting in network meta-analysis? A scoping review of network meta-analyses.

06 05 2023
DOI: 10.1186/s13643-023-02235-z PMID: 37149700

Evidence has shown that private industry-sponsored randomized controlled trials (RCTs) and meta-analyses are more likely to report intervention-favourable results compared with other sources of fundin... To (a) explore the recommendation rate of industry-sponsored NMAs on their company's intervention, and (b) assess reporting in NMAs of pharmacologic interventions according to their funding type.... Design: Scoping review of published NMAs with RCTs.... We used a pre-existing NMA database including 1,144 articles from MEDLINE, EMBASE and Cochrane Database of Systematic Reviews, published between January 2013 and July 2018.... NMAs with transparent funding information and comparing pharmacologic interventions with/without placebo.... We captured whether NMAs recommended their own or another company's intervention, classified NMAs according to their primary outcome findings (i.e., statistical significance and direction of effect), ... We retrieved 658 NMAs, which reported a median of 23 items in the PRISMA-NMA checklist (interquartile range [IQR]: 21-26). NMAs were categorized as 314 publicly-sponsored (PRISMA-NMA median 24.5, IQR ... Differences in completeness of reporting and author characteristics were apparent among NMAs with different types of funding. Publicly-sponsored NMAs had the best reporting and published their finding...

Humans Network Meta-Analysis Bias Checklist MEDLINE +1 autres

Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.

12 2023
DOI: 10.1111/ene.15872 PMID: 37204031

Therapy for myasthenia gravis (MG) is undergoing a profound change, with new treatments being tested. These include complement inhibitors and neonatal Fc receptor (FcRn) blockers. The aim of this stud... We assessed statistical heterogeneity across trials based on the Cochrane Q test and I... We observed an overall mean Myasthenia Gravis-Activities of Daily Living scale (MG-ADL) score change of -2.17 points (95% confidence interval [CI] -2.67, -1.67; p < 0.001) as compared to placebo. No s... Anti-complement and FcRn treatments both proved to be effective in MG patients, whereas rituximab did not show a significant benefit for patients. Within the limitations of this meta-analysis, includi...

Infant, Newborn Humans Rituximab Network Meta-Analysis Activities of Daily Living +3 autres

Effectiveness of aerobic exercise in the prevention and treatment of postpartum depression: Meta-analysis and network meta-analysis.

2023
DOI: 10.1371/journal.pone.0287650 PMID: 38019729

Aerobic exercise is widely recognized for improving mental health and reducing negative emotions, including anxiety. However, research on its role in preventing and treating postpartum depression (PPD... We conducted a quantitative systematic review of the study in 5 representative databases for the effect of aerobic exercise on PPD. Meta-analysis and network meta-analysis were performed with Review-M... Twenty-six studies with 2,867 participants were eventually included and the efficacy of aerobic exercise in preventing and treating postpartum depression is significant compared to standard care. (MD ... The efficacy of aerobic exercise in preventing and treating postpartum depression is significant compared to standard care, with a greater emphasis on prevention. The optimal prescribed exercise volum...

Female Humans Depression, Postpartum Network Meta-Analysis Exercise +1 autres

Antibiotic Prophylaxis in Reduction Mammaplasty: A Network Meta-Analysis.

06 2023
DOI: 10.1007/s00266-023-03313-2 PMID: 36928312

Mounting evidence suggests that breast reduction surgery displays higher rates of surgical site infections (SSI) than initially presumed. Objective of this network meta-analysis is to evaluate the eff... A network meta-analysis was conducted using a predetermined protocol after searching the electronic databases MEDLINE, Scopus, the Cochrane Library and US National Institutes of Health Ongoing Trials ... A total of 10 studies was included in the analysis involving 1331 patients. All but one study controlled for major risk factors, and no differences were observed in patients' baseline characteristics.... Antibiotics mitigate the SSI rate after breast reduction. This meta-analysis provides an evidence-based strategy to optimize antibiotic administration. Further research is needed though to examine ant... This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Inst...

Female Humans Surgical Wound Infection Antibiotic Prophylaxis Network Meta-Analysis +2 autres